Johannes F.E. Mann, M.D., from the Friedrich Alexander University of Erlangen in Germany, and colleagues reported the prespecified renal outcomes of a randomized controlled trial involving patients with type 2 diabetes receiving usual care who were assigned to liraglutide or placebo. A total of 9,340 patients were randomized and followed for a median of 3.84 years. The researchers found...
Tag: <span>Diabetic kidney disease</span>
Post
Suggests a novel treatment approach that may protect against diabetic kidney disease
George King, M.D., Chief Scientific Officer at Joslin Diabetes Center and Professor of Medicine at Harvard Medical School. More than 660,000 people in the United States suffer from end-stage kidney disease, which can only be treated by dialysis or kidney transplantation. Almost half of these patients develop the condition as a complication of diabetes....
Post
Promising Study Results for Diabetic Kidney Disease Seen with Mesoblast’s Cell Therapy
Mesoblast recently announced positive results from the placebo-controlled Phase 2 trial of its cell therapy MPC-300-IV for diabetic kidney disease patients. All results can be found in the paper “Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo Controlled, Dose Escalation Study,” published in the journal EBioMedicine. The clinical trial, conducted by researchers at the University...
- 1
- 2